Category — Healthcare
The Indian Institute of Technology Madras located in Chennai, India has developed Asia’s first ‘life-saving’ implant called SynkroScaff — A tissue engineered bovine pericardial patch — for critical cardiovascular patients. A Chennai-based firm, SynkroMax Biotech, has been appointed as the commercial partner. C.V. Seshadri, managing director of Synkromax Biotech said, “This sack is harvested and processed with biomaterial for ten days followed by quality control parameters to ensure it is microbial free.”
The pericardial patch (sack of buffalo’s heart) has inherent properties of regeneration and integration in the body, and its medical application is based on innovator Guhathakurta’s doctoral research in the institute in 2004, under the guidance of Venkatesh Balasubramanian, professor, Department of Engineering Design. Guhathakurta says, “Its applications are immense in cardiovascular and other surgical practices. So far, 800 patches have been manufactured and over 12 surgeons are using them across India. The feedback from doctors and patients has been encouraging, with a 100 percent success rate,” she said, adding that the product is manufactured in a facility complying with drug applications and current good manufacturing practice (cGMP) guidelines, reports the New Indian Express.
December 29, 2016 No Comments
In an interview with the Economic Times’ Healthworld, Dr. Richard M. Eglen, vice president and general manager of Corning Life Sciences, discussed the company’s business growth in India.
On Corning Life Science’s business in India
Eglen: India is one of our fastest growing markets in the Asia Pacific region. As a market, India has shown great potential and continues to grow significantly and drive growth for Corning Life Sciences outside of the U.S. With India’s population slated to reach 1.4 billion by 2022 (per the 2015 UN Report on World Population), this growing population demands not only large-scale production of vaccines, but also research for newer vaccines relevant to India.
Corning’s bioprocess products provide a full range of tools to successfully perform vaccine scale-up and production. Our cell culture products are of great interest to Indian pharmaceutical companies.
On Corning’s India’s revenue share
Eglen: The total sale of Asia represents over 50% of Corning’s total sales of US $ 9.1 billion worldwide in 2015. We can also tell you that we have more than doubled our revenues in India since 2009. 2015 was our strongest performance in Corning Life Science India history and we have kept the momentum going in 2016.
On future plans for the Indian market
Eglen: The Indian pharmaceutical market is currently at $25 billion and is expected to continue to grow at a CAGR of 12% till 2020. India is 3rd largest pharmaceutical market in the world by incremental growth and 7th largest by volume which gives Corning Life Sciences an immense growth opportunity. We have opened a warehouse for life sciences products for Indian customers in Mumbai which shows our commitment to be a reliable supplier for our customers in India.
December 29, 2016 No Comments
Microsoft India, and the L. V. Prasad Eye Institute, a not-for-profit comprehensive eye care institution in Hyderabad, India, have launched the Microsoft Intelligent Network for Eyecare (MINE), a machine learning network that will help doctors in India fight eye disease and reduce the risk of avoidable blindness.
Silicon ANGLE reports that Microsoft’s new AI network combines eye care data and research from a consortium of eye health institutes from around the world, including Bascom Palmer at the University of Miami, Flaum Eye Institute at the University of Rochester, the Federal University of Sao Paulo and the Brien Holden Vision Institute, Australia. Some of this data includes information specific to eye health in children, such as the rate of change of myopia in children and the conditions that impact children’s eyesight. Microsoft also hopes that MINE will be able to generate predictive models for eye surgery, allowing doctors to personalize treatment for each patient to maximize the chance for success.
Globally, 285 million people are visually impaired; 55 million of them live in India. “At L.V. Prasad Eye Institute, we have been using Microsoft Azure Machine Learning and Power BI to drive clinical interventions and improve patient outcomes,” said Dr. G.N.Rao, the eye institute’s founder-chair.
December 20, 2016 No Comments
Springboro, Ohio-based CleanLife Products that debuted in India earlier this year forecasts a turnover of $2 million by March 2017.
“India is a pretty big market. We have an order pipeline of $2 million, which is expected to close by March 2017. We are targeting $20 million in the next 5 years. India should contribute more than 20 percent of global sales in next 5 years,” founder and CEO Puneet Gupta told the Economic Times.
With a product portfolio that includes waterless shampoos, conditioners, body washes, shampoo caps and body wipes, the company is focused on the healthcare segment, defense industry, home care post surgery and products for seniors and the over-the-counter space in India. The products provide a comfortable alternative to traditional bathing methods, and the company has partnered with many hospitals in India.
Gupta added that in three years the company plans to set up its own manufacturing facility in India.
December 19, 2016 No Comments
Clariant, a specialty chemicals company headquartered in Muttenz, Switzerland, will commence its new greenfield production facility in Cuddalore in the southern state of Tamil Nadu by the second semester of 2017.
“The new site will serve the Indian pharmaceutical industry with state-of-the-art desiccant products produced under the strictest quality and compliance standards, and within a secure, truly global manufacturing network. We are extremely excited that facility construction, and production plans are moving at full speed ahead, according to schedule. The production capabilities at this new facility will add significantly to our global dessicant canister production capacity during 2017,” said Matthias Brommer, head – Clariant Healthcare Packaging.
This factory joins existing production facilities in the U.S., France and China, and it is strategically located within the Bangalore-Chennai biopharmaceutical cluster, one of India’s busiest pharmaceutical hubs, reports Business Standard.
December 18, 2016 No Comments